Angiotensin Converting Enzymes (ACE) Inhibitors Market

Angiotensin converting enzymes (ACE) inhibitors are a type of medication used primarily in the treatment of high blood pressure and heart failure. They work by blocking the action of a hormone called angiotensin II. Angiotensin II causes blood vessels to constrict and promotes the release of another hormone called aldosterone, which leads to water and salt retention in the body. By inhibiting the production of angiotensin II, ACE inhibitors help to relax and widen the blood vessels, reduce the amount of water retained by the body, and therefore lower blood pressure. Commonly prescribed ACE inhibitors include lisinopril, enalapril, and ramipril. Side effects can include dry cough, dizziness, and kidney problems. It is important for individuals taking ACE inhibitors to have regular check-ups to monitor their kidney function and potassium levels. ACE inhibitors play a pivotal role in mitigating the effects of angiotensin II, aiding in the relaxation and widening of blood vessels while regulating fluid retention, thus contributing significantly to blood pressure reduction.

Market Dynamics

The global angiotensin converting enzymes (ACE) inhibitors market’s growth is driven by the high prevalence of hypertension and heart disease globally. The body produces four distinct forms of the hormone angiotensin (an-gee-oh-ten-sin; the types' names are Roman numerals). Angiotensin I is converted to angiotensin II by ACE, which has a variety of bodily consequences. ACE inhibitors are often recommended, particularly for cardiovascular diseases and high blood pressure. An ACE inhibitor was given to over 12.9 million Medicare Part D participants in 2019 (or roughly 27% of all beneficiaries with Part D coverage). It is true that ACE inhibitors can cause negative effects. Most of them are mild, but a few are dangerous and require emergency medical attention.

Key features of the study:

• This report provides in-depth analysis of the global angiotensin converting enzymes (ACE) inhibitors market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis AG, Pfizer Inc., Merck & Co., AstraZeneca, Sanofi, Boehringer Ingelheim, GlaxoSmithKline, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mylan and Other Prominent Players
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global angiotensin converting enzymes (ACE) inhibitors market

Detailed Segmentation:

• Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs:
• • Benazepril
  • Perindopril
  • Trandfolapril
  • Captopril
  • Enalapril
  • Lisinopril
  • Others (Ramipril, etc.)
• Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication:
• • Hypertension
  • Coronary Artery Disease
  • Heart Failure
  • Chronic Kidney Disease
  • Scleroderma
  • Others (Migraine, etc.)
• Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration:
• • Oral
  • Injectable
• Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel:
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region:
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East &Africa
• Company Profiles:
• • Novartis AG
  • Pfizer Inc.
  • Merck & Co.
  • AstraZeneca
  • Sanofi
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd.
  • Reddy's Laboratories Ltd.
  • Mylan
  • Other Prominent Players